Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Cobitolimod as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis Patients

NCT01493960 is registered in ClinicalTrials.gov with InDex Pharmaceuticals as lead sponsor.

NCT NCT01493960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01493960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Cobitolimod as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis Patients
Lead sponsor
InDex Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2011
Completion date
March 31, 2014
Enrollment
131 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative